Comparison 4. Risperidone versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
4.1 Agitation	2	524	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.26 [‐0.44, ‐0.09]
4.2 Psychosis	5	1205	Std. Mean Difference (IV, Fixed, 95% CI)	‐0.11 [‐0.23, 0.01]
4.3 Somnolence	2	700	Risk Ratio (IV, Fixed, 95% CI)	3.35 [1.99, 5.65]
4.4 Extrapyramidal symptoms	6	1328	Risk Ratio (IV, Fixed, 95% CI)	1.75 [1.32, 2.33]
4.5 Any adverse event	2	700	Risk Ratio (IV, Fixed, 95% CI)	1.19 [1.07, 1.32]
4.6 Any serious adverse event	5	1085	Risk Ratio (IV, Fixed, 95% CI)	1.21 [0.88, 1.67]
4.7 Death	5	1298	Risk Ratio (IV, Fixed, 95% CI)	1.29 [0.64, 2.60]
4.8 Number of responders for agitation	2	572	Risk Ratio (IV, Fixed, 95% CI)	1.61 [1.29, 2.01]
4.9 Number of responders for psychosis	3	781	Risk Ratio (IV, Fixed, 95% CI)	1.05 [0.93, 1.19]
4.10 Discontinuation due to adverse events	5	1349	Risk Ratio (IV, Fixed, 95% CI)	1.60 [1.13, 2.27]
4.11 Discontinuation (any reason)	6	1383	Risk Ratio (IV, Fixed, 95% CI)	0.95 [0.85, 1.07]
4.12 Cognitive function	2	353	Mean Difference (IV, Fixed, 95% CI)	‐0.31 [‐1.04, 0.41]
4.13 Functioning (ADL)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.14 Health‐related quality of life	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
4.15 Time spend providing care (caregiver)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected